LFG
AMLX icon

Larson Financial Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Larson Financial Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.79K Buy
201
+160
+390% +$2.25K ﹤0.01% 2860
2025
Q4 		$495 Buy
+41
New +$557 ﹤0.01% 3126

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Larson Financial Group's AMLX Position: Q1 2026 in Review

Larson Financial Group increased its Amylyx Pharmaceuticals (AMLX) stake by 390% in Q1 2026, buying an estimated $2.25K and bringing the position to 201 shares worth $2.79K. The position accounts for ﹤0.01% of the portfolio, ranked #2860.

Larson Financial Group first reported a position in AMLX in Q4 2025 and has held it in 2 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Larson Financial Group held 201 shares of Amylyx Pharmaceuticals worth $2.79K as of Q1 2026.
  • Larson Financial Group bought 160 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $2.25K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2860 holding.
  • Larson Financial Group first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.